Semax Research Peptide

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro.

• Semax peptide is a descriptive search term, while N-acetyl Semax amidate and other modified versions are chemically distinct and should not be treated as interchangeable.

Semax combines an ACTH(4-7)-related sequence with the C-terminal tripeptide Pro-Gly-Pro.

• It is studied as a synthetic neuroactive peptide rather than as a conventional GLP-1, GHRH, or repair peptide.

Research examines neurotrophin-related gene expression, neural and neuroimmune signaling, ischemia models, stress responses, and neurotransmitter systems.

• Common experimental endpoints include changes in BDNF, NGF, receptor transcription, cytokine signaling, and animal behavior.

The literature contains substantial regional laboratory and clinical reporting, but large, internationally replicated controlled human trials remain limited.

• Molecular changes and animal-model findings do not by themselves establish a cognitive or neurological clinical effect.
• Differences in sequence and delivery route also make direct comparisons between studies difficult.

Regulatory status differs by country, and Semax is not an FDA-approved medicine in the United States.

• Evidence from one sequence, salt, delivery system, or formulation cannot be applied automatically to research-labeled sprays, powders, or modified analogues.